Primidone, phenobarbital, and PEMA: II. Seizure protection, neurotoxicity, and therapeutic index of varying combinations in mice.
Neurotoxicity and protection against maximal electroshock (MES) and pentylenetrazol (Metrazol) seizures were determined in mice for various combinations of primidone (PRM), phenobarbital (PB), and phenylethylmalonamide (PEMA). The results suggest that PRM and PB together are superior to either one alone in terms of spectrum of activity and relative toxicity. The protection against Metrazol and the toxicity of PB are both potentiated by PEMA at low concentrations. PEMA also potentiates the toxicity of combined PRM plus PB, without altering their protection against MES, thus lowering their therapeutic index. We conclude that PRM and PB together have an advantage over PB alone, especially when their brain concentration ratio is at or above 1 and PEMA concentrations are low. These conditions are usually not present at steady state in patients treated with PRM.
D000818:Animals; D001921:Brain / Q000187:drug effects; D001923:Brain Chemistry; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004597:Electroshock; D005260:Female; D008314:Malonates / Q000008:administration & dosage*; D051379:Mice; D008815:Mice, Inbred Strains; D010433:Pentylenetetrazole; D010634:Phenobarbital / Q000008:administration & dosage* / Q000633:toxicity; D010657:Phenylethylmalonamide / Q000008:administration & dosage* / Q000633:toxicity; D011324:Primidone / Q000008:administration & dosage* / Q000633:toxicity; D012640:Seizures / Q000139:chemically induced / Q000188:drug therapy*
D008314:Malonates; D011324:Primidone; D010657:Phenylethylmalonamide; D010433:Pentylenetetrazole; D010634:Phenobarbital